
    
      Sub-Study 1: COVID-19 patients in self-quarantine. Arm 1: Hydroxychloroquine 400 mg bid (two
      200 mg tablets taken twice a day; totaling 800 mg per day) for two weeks; Arm 2: Placebo 2
      pills twice a day for two weeks

      Sub-Study 2: Asymptomatic health care worker prophylaxis. Arm 1: Hydroxychloroquine 600 mg
      once a day (three 200 mg tablets taken once a day) for up to 2 months; Arm 2: Placebo 3 pills
      once a day for up to 2 months; cross-over from placebo to HCQ 600 mg once a day is allowed
      upon confirmatory diagnosis for COVID-19.

      PRIMARY OBJECTIVES:

      Sub-Study 1 (Patients tested for COVID-19 who meet symptomology and age requirements for
      eligibility): Rate of hospitalization

      Sub-Study 2 (Health Care Workers): Rate of COVID-19 infection (confirmed by accepted testing
      methods) at 2 months

      SECONDARY OBJECTIVES Sub-Study 1: Rate of secondary infection of co-inhabitants, adverse
      events, and negative for COVID-19 (confirmed by accepted testing methods) at 14 days

      Sub-Study 2: Number of shifts missed; rate of adverse events, and hospitalization at 2 months
    
  